Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 64 results found. Search for [ covaxin side effects ]

Results 1 to 21 of 64
BusinessToday.In
New Delhi, April 22, 2021
Adar Poonawalla, CEO, Serum Institute of India, explains the impact of the Covishield vaccine on the double mutant strain present in India. In an exclusive conversation with India Today, Poonawalla said that the COVID vaccines were initially developed with an idea to reduce the death numbers, keep people away from getting hospitalised and lower the burden on doctors. He added that Covishield has displayed 90% efficacy against all coronavirus variants, keeping people away from the need for oxygen and ventilators. On the other hand, the healthcare sector is going through an acute shortage of beds, ventilators and oxygen in India. Watch the video for more details. Also Read: COVID-19: Pfizer to supply coronavirus vaccine at 'not-for-profit' rate to Centre


BusinessToday.In
April 9, 2021
Dr Vardhan says over 89 lakh healthcare workers have got the first dose and over 54 lakhs have got the second dose. As far as frontline or field level workers are concerned, over 98 lakhs got the first dose and over 45 lakhs have got the second dose, he adds


BusinessToday.In
New Delhi, April 9, 2021
Thirty-seven doctors have tested positive for coronavirus at Delhi's Sir Ganga Ram Hospital. Out of these, 32 doctors are in home isolation whereas 5 are hospitalised for treatment. The majority of these doctors have mild symptoms. What has surprised everyone is that all these doctors had been vaccinated for COVID-19. The second wave of the pandemic in India is proving to be worse than the first with infections skyrocketing and large clusters of infections are being reported from different areas. Will the second wave prove worse than the first despite vaccinations? Watch the video for more.Also Read: Govt panel to probe side effects of Covishield, Covaxin vaccines


BusinessToday.In
New Delhi, April 9, 2021
Following RBI Governor Shaktikanta Das' announcements on Wednesday, the apex bank notified on Thursday that it would conduct open market purchase of government securities of Rs 1 lakh crore under the G-sec Acquisition Programme (G-SAP); After a brief halt, India accelerated the work on Chabahar Port early this year and the strategic Iranian port is expected to be operational by next month; Australia and the Philippines limited use of AstraZeneca's COVID-19 vaccine on Thursday, while the African Union dropped plans to buy the shot amid global shortages, dealing further blows to the company's hopes to deliver a vaccine for the world. Watch this and more news on News Blast.Also Read: Govt panel to probe side effects of Covishield, Covaxin vaccines


BusinessToday.In
April 9, 2021
Centre's clarification comes amid an ongoing debate over the export of vaccines with some states, mostly non-BJP ruled, flagging the issue of shortage of vaccines


BusinessToday.In
April 9, 2021
India coronavirus update: Active cases have continued to scale up to 9,79,608 which comprise 7.5 per cent of the total infections. Likewise, coronavirus-related deaths are also accelerating as hospitals get overwhelmed


BusinessToday.In
April 9, 2021
The move by the national committee on adverse effects following immunisation (AEFI) has come after the European's regulator said it found rare cases of blood clots among some adult recipients who were given AstraZeneca-Oxford university's vaccine shots


Reuters
March 31, 2021
Acting on advice from Germany's vaccine committee, known as STIKO, the ministries also agreed the Anglo-Swedish firm's vaccine could be used for high-risk patients aged below 60 as well as for high-priority groups such as medical workers


BusinessToday.In
March 30, 2021
Dr Harsh Vardhan said that the situation is under control but there is no place for complacency in terms of observing appropriate COVID behaviour


BusinessToday.In
March 23, 2021
Until now, healthline workers, frontline workers, people above 60 years, and those aged 45 and above with comorbidities were eligible to take the COVID-19 vaccine shots


BusinessToday.In
March 20, 2021
During the Question Hour in Lok Sabha on Friday, Vardhan said 3.5 to 4 crore people have been vaccinated so far in India and side effects have been detected in only 0.000432% of vaccine recipients


BusinessToday.In
March 18, 2021
Out of 38 autopsy reports, the National Adverse Events Following Immunisation (AEFI) committee reviewed of people who died after receiving the vaccination, nothing linked the deaths or adverse events to vaccination


BusinessToday.In
March 18, 2021
The hospital's Resident Doctors Association (RDA) has decided to take this step to press for the release of their pending salaries


BusinessToday.In
March 17, 2021
In a meeting with state-level monitoring committees on Tuesday, March 17, the Union Health Ministry asked states to do it for both Covaxin and Covishield vaccines


PTI
March 13, 2021
India has reported 234 adverse events following immunisation (AEFIs), including 71 deaths, for both the vaccines till Friday, said Dr N K Arora, an advisor to the national AEFI committee


BusinessToday.In
March 12, 2021
Denmark suspended the AstraZeneca Covid-19 vaccine on Thursday after many recipients reported blood clotting and one among them has allegedly \"died\". Norway and Iceland also followed the suit, scrapping the vaccine administration


BusinessToday.In
March 11, 2021
The Union Health Ministry has stated that 90 lakh people have been given Covaxin so far as part of the nationwide COVID-19 vaccination drive and only 307 people have experienced some side effects from taking the vaccine


Rashi Bisaria
New Delhi, March 10, 2021
Covaxin safe, immunogenic with no side effects, says Lancet Medical peer-review journal Lancet has published the interim results for phase 2 trials of Bharat Biotech's COVID-19 vaccine, Covaxin, calling it 'safe, immunogenic with no serious side effects'. The double-blind, randomised, multicentre, phase 2 clinical trial to evaluate the immunogenicity and safety of Covaxin (BBV152) in healthy adults and adolescents (aged 12-65 years) was carried out at nine hospitals in India. Data breach c...


BusinessToday.In
New Delhi, March 9, 2021
Star and Disney India launches diversity resource group for women, LGBTQ employees; Indian Railways integrates all helpline numbers into single Rail Madad Helpline 139; FM Sitharaman credits govt's fiscal measures for 0.4% GDP growth in Q3. Watch this and more news on News Blast.Also Read: Covaxin safe, immunogenic with no side effects, says Lancet


BusinessToday.In
March 9, 2021
The most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever.


PAGES 1 OF 4  1234